

Status: Currently Official on 15-Feb-2025
 Official Date: Official as of 01-May-2016
 Document Type: USP Monographs
 DocId: GUID-A0B3A367-A8CD-425F-9314-19ABA2C59C2A_1_en-US
 DOI: https://doi.org/10.31003/USPNF_M36360_01_01
 DOI Ref: a414m

© 2025 USPC
 Do not distribute

Halcinonide Cream

DEFINITION

Halcinonide Cream is Halcinonide in a suitable cream base. It contains NLT 90.0% and NMT 110.0% of the labeled amount of halcinonide ($C_{24}H_{32}ClFO_5$).

IDENTIFICATION

- **A.** The retention time of the halcinonide peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.
- **B.** The UV-Vis spectrum of the halcinonide peak of the *Sample solution* corresponds to that of the *Diluted standard stock solution*, as obtained in the test for *Organic Impurities*.

ASSAY

• PROCEDURE

Mobile phase: Acetonitrile and water (50:50)

Diluent: Acetonitrile and water (2:1), saturated with hexanes. [NOTE—Prepare on the day of use.]

Internal standard solution: 150 µg/mL of progesterone in hexanes-saturated *Diluent*

Standard stock solution: 0.2 mg/mL of [USP Halcinonide RS](#) in *Diluent*

Standard solution: 0.02 mg/mL of [USP Halcinonide RS](#) in hexanes-saturated *Diluent* prepared as follows. Transfer 5.0 mL of *Standard stock solution* to a 50-mL volumetric flask. Add 4.0 mL of *Internal standard solution*, and dilute with hexanes-saturated *Diluent* to volume.

Sample solution: Nominally 0.02 mg/mL of halcinonide in hexanes-saturated *Diluent* prepared as follows. Transfer a quantity of Cream equivalent to 0.5 mg of halcinonide to a glass-stoppered, 50-mL centrifuge tube. Add 12 mL of hexanes-saturated *Diluent* and 20 mL of hexanes, and shake for 1 min. Place in a heated ultrasonic bath at $58 \pm 2^\circ$ for 20 min, initially shaking for 1–2 min to ensure dispersion, and at 5-min intervals thereafter, on a vibratory mixer. Cool, centrifuge, and transfer the lower layer to a 25-mL volumetric flask. Add 5 mL of hexanes-saturated *Diluent* to the tube, mix for 1 min, then centrifuge. Transfer the lower layer to the volumetric flask, and repeat the extraction with an additional 5 mL of hexanes-saturated *Diluent*, combining the extracts in the flask. Add 2.0 mL of *Internal standard solution* to the flask, dilute with hexanes-saturated *Diluent* to volume, and mix. If necessary, clarify a portion of the solution by centrifugation.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 254 nm

Column: 4-mm × 30-cm; packing L1

Flow rate: 2 mL/min

Injection volume: 20 µL

System suitability

Sample: *Standard solution*

[NOTE—The relative retention times for halcinonide and progesterone are 1.0 and 1.2, respectively.]

Suitability requirements

Resolution: NLT 1.5 between halcinonide and progesterone

Relative standard deviation: NMT 3.0%, peak response ratio of halcinonide to progesterone

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of halcinonide ($C_{24}H_{32}ClFO_5$) in the portion of Cream taken:

$$\text{Result} = (R_U/R_S) \times (C_S/C_U) \times 100$$

R_U = peak response ratio of halcinonide to progesterone from the *Sample solution*

R_s = peak response ratio of halcinonide to progesterone from the *Standard solution*

C_s = concentration of [USP Halcinonide RS](#) in the *Standard solution* (mg/mL)

C_u = nominal concentration of halcinonide in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

- [MINIMUM FILL \(755\)](#): Meets the requirements

IMPURITIES

- [ORGANIC IMPURITIES](#)

Solution A: 10 mM of ammonium acetate in water

Solution B: Acetonitrile

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	90	10
20.0	10	90
22.0	10	90
22.1	90	10
25.0	90	10

Diluent 1: Acetonitrile and water (60:30), saturated with hexanes

Diluent 2: Acetonitrile and water (10:90)

Standard stock solution: 0.2 mg/mL of [USP Halcinonide RS](#) in *Diluent 1*

Diluted standard stock solution: 0.1 mg/mL of [USP Halcinonide RS](#) in *Diluent 2* from the *Standard stock solution*

Standard solution: 0.2 µg/mL of [USP Halcinonide RS](#) in *Diluent 2* from the *Standard stock solution*

Sample stock solution: Nominally 0.2 mg/mL of halcinonide in *Diluent 1* prepared as follows. Transfer a portion of Cream equivalent to 4 mg of halcinonide to a 50-mL centrifuge tube. Add 10 mL of *Diluent 1* and 20 mL of hexanes heated at 58 ± 2° for 20 min. Shake for NLT 1 min initially to ensure dispersion and at 5-min intervals thereafter. Cool, centrifuge at 3000 rpm for 10 min, and transfer the lower layer to the 20-mL volumetric flask. Repeat the extraction with an additional 5 mL of *Diluent 1* and 20 mL of hexanes each time. Dilute with *Diluent 1* to volume.

Sample solution: 0.1 mg/mL of halcinonide from *Sample stock solution* in *Diluent 2*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 240 nm. For *Identification test B*, use a diode array detector in the range of 200–450 nm.

Column: 2.1-mm × 15-cm; 1.7-µm packing L1

Flow rate: 0.3 mL/min

Injection volume: 10 µL

System suitability

Sample: *Standard solution*

[**NOTE**—See [Table 2](#) for relative retention times.]

Suitability requirements

Relative standard deviation: NMT 2.4%

Signal-to-noise ratio: NLT 50

Analysis

Samples: *Diluted standard stock solution*, *Standard solution*, and *Sample solution*

[**NOTE**—The *Diluted standard stock solution* is used for *Identification test B*.]

Calculate the percentage of any individual unspecified impurity in the portion of Cream taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of each individual unspecified impurity from the *Sample solution*

r_S = peak response of halcinonide from the *Standard solution*

C_S = concentration of [USP Halcinonide RS](#) in the *Standard solution* ($\mu\text{g/mL}$)

C_U = nominal concentration of halcinonide in the *Sample solution* ($\mu\text{g/mL}$)

Acceptance criteria: See [Table 2](#).

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Dihydrotriamicinolone ^a	0.5	—
Halcinonide	1.0	—
Any individual unspecified impurity	—	0.2
Total impurities	—	3.0

^a Drug substance process impurity included in the table for identification only.

SPECIFIC TESTS

- [MICROBIAL ENUMERATION TESTS \(61\)](#) and [TESTS FOR SPECIFIED MICROORGANISMS \(62\)](#): Meets the requirements for absence of *Staphylococcus aureus* and *Pseudomonas aeruginosa*

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers. Store at room temperature. Avoid excessive heat.
- [USP REFERENCE STANDARDS \(11\)](#).
[USP Halcinonide RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
HALCINONIDE CREAM	Documentary Standards Support	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 40(4)

Current DocID: GUID-A0B3A367-A8CD-425F-9314-19ABA2C59C2A_1_en-US

DOI: https://doi.org/10.31003/USPNF_M36360_01_01

DOI ref: [a414m](#)